Publication | Closed Access

PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival

UrologyGenitourinary CancerMedicinePharmacologyRetrospective AnalysisAbiraterone And/or EnzalutamideRadiopharmaceutical TherapyPharmacotherapyCancer TreatmentProstatic DiseaseOncologyOverall SurvivalMolecular Oncology